ACRS
Aclaris Therapeutics Inc
NASDAQ · Pharmaceuticals
$3.57
+0.18 (+5.31%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 26.24M | 18.69M | 98.57M | 98.24M | 89.38M |
| Net Income | -185,107,858 | -118,633,534 | 16.17M | 16.97M | 14.96M |
| EPS | — | — | — | — | — |
| Profit Margin | -705.5% | -670.2% | 16.4% | 17.3% | 16.7% |
| Rev Growth | +40.4% | +40.4% | -5.0% | +7.1% | +11.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 145.22M | 169.20M | 162.32M |
| Total Equity | — | — | 161.20M | 157.50M | 149.90M |
| D/E Ratio | — | — | 0.90 | 1.07 | 1.08 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -195,129,793 | -132,004,061 | 25.50M | 25.23M | 23.19M |
| Free Cash Flow | — | — | 16.19M | 16.84M | 23.02M |